Building microbiological quality during the manufacture of medicines
25 min
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Biochemistry
-
8 min
1. De novo designed proteins: a breakthrough in snakebite treatment- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
24 min
-
26 min
3. From lab to clinic: bridging cancer genetics and public health- Prof. Clare Turnbull
-
21 min
4. Engineered yeast: a breakthrough in targeted cancer therapies- Prof. Gautam Dantas
-
9 min
-
18 min
6. Cancer vaccines- Dr. Elias Sayour
-
11 min
7. The future of blood tests in cancer treatment- Dr. Isaac Garcia-Murillas
-
15 min
-
14 min
9. Artificial intelligence in precision medicine- Dr. Michael P. Menden
-
18 min
10. How liver X receptor regulates intestinal regeneration and tumor growth- Dr. Srustidhar Das
- Immunology & Inflammation
-
14 min
11. Role of ETS2 in autoimmune and inflammatory diseases- Dr. James Lee
-
29 min
12. Rheumatic diseases and musculoskeletal pain- Prof. Anisur Rahman
-
13 min
-
16 min
14. Transmembrane domains and the regulation of trogocytosis in T cells- Dr. Stefano Barbera
-
12 min
- Infectious Diseases/Microbiology
-
13 min
16. Kalihinol analog MED6-189: a promising pan-antimalarial candidate- Prof. Karine Le Roch
-
31 min
17. Elite controllers of HIV: from discovery to future therapies- Prof. Bruce Walker
-
8 min
-
23 min
19. Towards developing a universal influenza vaccine- Prof. Peter Palese
-
10 min
- Methods
-
21. How big data and genomics are personalizing your health- Prof. Michael Snyder
-
21 min
22. The role of preregistration and registered reports in improving research transparency and reproducibility- Dr. Peter Bonde Ernst-Rasmussen
-
17 min
23. Decoding aging: how a proteomic clock predicts mortality and disease across populations- Dr. M. Austin Argentieri
-
10 min
24. MassBank development and future- Dr. Emma L. Schymanski
-
25 min
25. Synthetic whole embryo models and their applications- Prof. Jacob (Yaqub) Hanna
-
14 min
26. Pioneering proteomics: insights on advancements in the science of proteins- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
27. Duchenne muscular dystrophy: pathology, diagnostic strategies, and core molecular pathways- Prof. Steve Wilton
-
14 min
28. Rethinking the amyloid dogma in Alzheimer’s disease- Prof. George Perry
-
8 min
29. Integrated multimodal cell atlas of Alzheimer’s disease- Dr. Michael Hawrylycz
-
17 min
30. How and why neurons die in Alzheimer's disease?- Prof. Bart De Strooper
-
17 min
31. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD- Prof. Katrin Andreasson
-
18 min
32. Advancing ALS genetics through accessible testing- Dr. Teresa Fecteau
-
13 min
33. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
25 min
34. Translational research in amyotrophic lateral sclerosis (ALS)- Prof. Aaron D. Gitler
-
20 min
35. Muscarinic acetylcholine receptor modulation in neurological diseases- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
19 min
36. The state of the art in secondary pharmacology- Dr. Jean-Pierre Valentin
-
19 min
37. The safety, toxicology, and regulation of antibody-drug conjugates- Dr. Veysel Kayser
-
18 min
-
31 min
39. Management of generic drug development: challenges and opportunities- Mr. Sandeep Patil
-
30 min
40. Translational medicine: the risk of failure in delay and how to reduce it- Prof. Martin Wehling
-
17 min
41. Artificial intelligence in guiding cancer treatment decisions- Prof. Eytan Ruppin
-
13 min
42. The regulation of cell therapy- Prof. Moutih Rafei
-
31 min
43. Scale-up challenges in the production of nanomedicines from lab to industry- Prof. Dr. Oya Tagit
-
8 min
44. Challenges and solutions of scaling up- Dr. Shaukat Ali
-
11 min
-
14 min
46. Using real-world insights on drug interactions to inform drug development- Dr. Amita Datta-Mannan
-
50 min
47. Role of marketing authorization holder in drug safety- Dr. Raphael Elmadjian Pareschi
Topics Covered
- Data sources and AI in pharmacovigilance
- Personalized medicines
- Key challenges
- Early access to medicines
- Real-world evidence
Biography
Prof. Saad Shakir is a leading pharmacoepidemiologist and drug safety expert, best known for his 26 years as Director of the independent Drug Safety Research Unit (DSRU), affiliated with the University of Portsmouth. Trained in clinical pharmacology and with a background in hospital medicine and general practice, he joined the UK Medicines Control Agency before taking up the DSRU role in 1999. Under his leadership, the unit expanded its methodologies from Prescription Event Monitoring to innovative real-world approaches, including registries, data linkage studies, and benefit–risk assessments, strengthening its global reputation in pharmacovigilance. A Fellow of multiple Royal Colleges and the Faculty of Pharmaceutical Medicine, and an active contributor to international journals and postgraduate education, Prof. Shakir has made influential contributions to drug safety science and training worldwide.
Talk Citation
Shakir, S. (2025, September 30). Pharmacovigilance: recent advancements (2025) [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 14, 2026, from https://doi.org/10.69645/DQRB6774.Export Citation (RIS)
Publication History
- Published on September 30, 2025
Financial Disclosures
- Prof. Saad Shakir has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Pharmacovigilance: recent advancements (2025)
Published on September 30, 2025
11 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...